WHAT IS THIS?

This is a large contract between the National Cancer Institute (NCI), which is part of the Department of Health and Human Services, and Leidos Biomedical Research Inc., a company that supports scientific and medical programs. The company is paid to handle day-to-day operations and support services that keep NCI's research programs running.

WHY WAS THIS FUNDED?

The NCI is a federal agency with a legal mission to conduct and support cancer research across the United States. This contract was issued as a 'task order,' meaning it falls under a larger pre-approved contract vehicle that allows the government to purchase specific services as needed.

WHAT PUBLIC PROBLEM IS IT TRYING TO SOLVE?

Cancer is one of the leading causes of death in the United States, and federal investment in research helps scientists find better ways to prevent, detect, and treat it. This contract helps keep the people, labs, and systems behind that research functioning every day.

WHO BENEFITS?

Scientists, researchers, and staff working at NCI facilities benefit directly, as do cancer patients who may eventually gain from advances in treatment and early detection. The broader American public benefits from a functioning national cancer research infrastructure.

WHAT ARE THE RISKS?

A contract of this size, nearly 1.8 billion dollars over four years, carries risks around cost overruns, oversight gaps, and whether taxpayers are getting good value for the services delivered. Because the contract type is listed as unknown, it is harder to assess how costs and performance are being monitored.

WHAT HAPPENS IF FUNDING IS REMOVED?

If this contract were cancelled, NCI's operational support functions could be significantly disrupted, potentially slowing or halting ongoing cancer research programs. Staff, labs, and administrative systems that depend on this contractor would need replacement quickly or research timelines could be delayed.

ARGUMENTS FOR

• •Supporting NCI operations through a specialized contractor allows cancer research to continue at scale, which could lead to life-saving medical breakthroughs for millions of Americans.
• •Using an outside contractor for operational tasks can free up government scientists to focus on research rather than administrative and logistical work.
• •Leidos Biomedical Research Inc. has an established history supporting NCI, which may reduce the learning curve and improve efficiency compared to starting fresh with a new provider.

ARGUMENTS AGAINST

• •At nearly 1.8 billion dollars, this is an enormous sum, and without a clear contract type on record, it is difficult for the public to verify whether spending controls and performance standards are adequate.
• •Relying heavily on a single private contractor for core government research operations can create dependency and reduce the government's ability to change course if performance falls short.
• •Large sole-source or long-term contracts in general can limit competition, which may result in higher costs compared to what a more competitive bidding process might achieve.